Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer

BACKGROUND. Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity. The tolerability and efficacy of lower starting doses of sorafenib for DTC remain largely unstudied. METHODS. We retrospecti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dadu, Ramona, Waguespack, Steven G., Sherman, Steven I., Hu, Mimi I., Busaidy, Naifa L., Jimenez, Camilo, Habra, Mohammed A., Ying, Anita K., Bassett, Roland L., Cabanillas, Maria E.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4012968/
https://ncbi.nlm.nih.gov/pubmed/24733667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0409
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados